| Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET. | |
| | |
MedLine Citation:
|
PMID: 18458598 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND OBJECTIVES: Currently, there is no definite consensus regarding the best index to assess disease activity with fluorodeoxyglucose-PET imaging. Maximum standardized uptake value (SUVmax) is most frequently used in day-to-day practice for this purpose. This approach very often reflects the metabolic activity of only a small sample of the total ongoing process in the entire body. Here we introduce a new concept called metabolic burden (MB) to measure disease activity in cancer patients. MATERIALS AND METHODS: MB was calculated by measuring the volume (VCT) around a lesion that appeared on computed tomography (CT), the mean SUV that appeared on PET of the CT volume (SUVmean CT), and the recovery coefficient (RC) using the following formula: (Equation is included in full-text article.) If CT was unavailable, a region of interest (ROI) around the lesion was defined by a 40% SUVmax threshold and the volume and SUVmean were determined for that ROI. The whole-body metabolic burden (WBMB) was calculated as the sum of the individual MBs of all the lesions identified. We retrospectively reviewed 19 patients with non-Hodgkin's lymphoma who were treated with commercially available anti-CD20 radioimmunotherapy agents or conventional chemotherapy. All had a pretreatment and posttreatment fluorodeoxyglucose-PET and CT scan within 1-3 months of receiving systemic therapy. Either abnormal areas appearing on PET alone or corresponding lesions on CT were used to calculate the tumor volume (TV). Nodes of less than 2 cm occurring in clusters were grouped together into a single ROI. Thirty-eight regional collections in 14 patients were found in combined pretreatment and posttreatment studies and were assessed. The TVs varied in pretreatment size from 5.8 to 857 cm and posttreatment from 0 to 81 cm. Pretreatment WBMB varied from 27 to 10 218 cm and posttreatment from 0 to 279 cm. We then compared the standard indices of SUVmean and SUVmax with those of WBMB to determine which of the indices would have the best sensitivity as a predictor of therapeutic response. RESULTS: Five of the 19 patients had a complete response. In 14 patients with partial response, the average change in WBMB was 80%, the TV decreased by 76%, the SUVmax decreased by 42%, and the SUVmean decreased by 38.5%. CONCLUSION: The results of this analysis demonstrate that measurement of WBMB may prove to be superior to the existing methods in assessing and managing patients with non-Hodgkin's lymphoma. This index may be the best way to monitor the changes in WBMB as a patient is undergoing treatment. |
| | |
Authors:
|
Arnold Berkowitz; Sandip Basu; Shyam Srinivas; Shrinkanthan Sankaran; Stephen Schuster; Abass Alavi |
Related Documents
:
|
15232708 - Value of (124)i-pet/ct in staging of patients with differentiated thyroid cancer. 17530248 - Non-enhanced ct versus contrast-enhanced ct in integrated pet/ct studies for nodal stag... 16319618 - Current use of 18f-fluorodeoxyglucose positron emission tomography and combined positro... 17873168 - Noninvasive staging of non-small cell lung cancer: accp evidenced-based clinical practi... 20957888 - An unusual cause of pelvic hemorrhage: multidetector ct diagnosis of inferior mesenteri... 21312068 - Pancreatoduodenal junction: review of anatomy and pathologic conditions. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Nuclear medicine communications Volume: 29 ISSN: 0143-3636 ISO Abbreviation: Nucl Med Commun Publication Date: 2008 Jun |
Date Detail:
|
Created Date: 2008-05-06 Completed Date: 2008-07-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8201017 Medline TA: Nucl Med Commun Country: England |
Other Details:
|
Languages: eng Pagination: 521-6 Citation Subset: IM |
Affiliation:
|
Division of Nuclear Medicine, Hospital of University of Pennsylvania, Philadelphia 19104, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Algorithms* Female Fluorodeoxyglucose F18 / diagnostic use*, pharmacokinetics* Humans Image Interpretation, Computer-Assisted / methods* Lymphoma / metabolism*, radionuclide imaging* Male Middle Aged Radiopharmaceuticals / diagnostic use, pharmacokinetics Severity of Illness Index Tissue Distribution Whole Body Imaging / methods* |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: UK audit of glomerular filtration rate measurement in 2001.
Next Document: Role of serial quantitative gallium-67 tumor uptake in assessing response rates for chemotherapy in ...